Alkeon Capital Management
RYTM icon

Alkeon Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Alkeon Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,017,700
Closed -$103M – 122
2025
Q3 		$103M Hold
1,017,700
– – 0.15% 64
2025
Q2 		$64.3M Buy
1,017,700
+200,000
+24% +$12.2M 0.11% 68
2025
Q1 		$43.3M Sell
817,700
-350,000
-30% -$19.4M 0.09% 84
2024
Q4 		$65.4M Hold
1,167,700
– – 0.13% 64
2024
Q3 		$61.2M Buy
1,167,700
+167,700
+17% +$8.04M 0.1% 67
2024
Q2 		$41.1M Buy
+1,000,000
New +$39.9M 0.07% 83
2023
Q4 		– Sell
-1,725,167
Closed -$39.5M – 104
2023
Q3 		$39.5M Hold
1,725,167
– – 0.07% 80
2023
Q2 		$28.4M Sell
1,725,167
-290,799
-14% -$5.25M 0.05% 90
2023
Q1 		$36M Sell
2,015,966
-222,296
-10% -$5.58M 0.08% 89
2022
Q4 		$65.2M Buy
2,238,262
+533,262
+31% +$13.7M 0.25% 78
2022
Q3 		$41.8M Buy
1,705,000
+205,000
+14% +$3.81M 0.14% 98
2022
Q2 		$6.22M Buy
+1,500,000
New +$8.21M 0.02% 131
2018
Q1 		– Sell
-25,000
Closed -$727K – 124
2017
Q4 		$727K Buy
+25,000
New +$661K ﹤0.01% 85

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alkeon Capital Management's RYTM Position: Q4 2025 in Review

Alkeon Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 1,017,700 shares — an estimated $103M sold.

Alkeon Capital Management first reported a position in RYTM in Q4 2017 and held it in 13 quarters. The position peaked at $103M in Q3 2025. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • Alkeon Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Alkeon Capital Management sold 1,017,700 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $103M.
  • Alkeon Capital Management first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 13 quarters.
  • Alkeon Capital Management's Rhythm Pharmaceuticals position peaked at $103M in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Alkeon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.